Inclusion Criteria:

1. Signed written informed consent;

2. Female outpatient aged 18 years or older;

3. Subjects must be about to begin their initial treatment with lapatinib + capecitabine
for HER2+ metastatic or advanced breast cancer according to physician's clinical
judgement as per local prescribing information

4. Subjects must be literate, be able to read, understand and write local language.

Exclusion Criteria:

1. Women who is participating in any other interventional clinical trials concurrently;

2. Women who is already taking or had taken lapatinib + capecitabine regimen prior to
the enrollment;

3. Primary lesions that are not of breast origin.